Servier and the Belgium-based biotechnology company Galapagos are embarking on a multiyear strategic alliance to develop new cancer therapies. As a result of the alliance, Galapagos could receive milestone payments of more than EUR 250 million ($332 million).
Servier and the Belgium-based biotechnology company Galapagos are embarking on a multiyear strategic alliance to develop new cancer therapies. As a result of the alliance, Galapagos could receive milestone payments of more than EUR 250 million ($332 million).
The alliance will build on a combination of novel oncology targets from both companies. Galapagos will be responsible for the discovery and development of new candidate drugs, and Servier will have the exclusive option to license each small-molecule program after Galapagos has completed preclinical development. In exercising this option, Servier will be responsible for further clinical development, registration, and commercialization. However, Galapagos will retain exclusive rights for clinical development, registration, and commercialization in the US.
“In this new alliance, Servier and Galapagos combine both their oncology targets and their capabilities in cancer drug discovery,” said Onno van de Stolpe, CEO of Galapagos, in a press statement. “Similar to our osteoarthritis alliance with Servier, Galapagos retains the US rights, which represents a large potential, considering the unmet medical need in cancer.”
Galapagos will receive research access payments of EUR 2 million ($2.65 million) from Servier and will also be eligible for discovery, development, regulatory, and other milestone payments that could reach EUR 260 million ($345 million), plus royalties, upon commercialization of products by Servier.
“Based on the progress made already in our osteoarthritis collaboration with Galapagos, we are convinced of Galapagos’s ability to deliver new cancer drugs based on novel targets. This alliance complements our very innovative cancer pipeline,” said Emmanuel Canet, Head of R&D at Servier, in the press statement.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.